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Abstract
Cell-to-cell communication has a critical role during tumor development and progression, allowing cancer cell to
re-program not only the surrounding tumor microenvironment, but also cells located at distant sites. The crosstalk
between neoplastic cells and accessory elements, such as immune and stromal cells, fosters several processes that
are necessary for tumor progression and dissemination, such as angiogenesis, immune-escape, epithelial-to-
mesenchymal transition, invasion and multi-drug resistance. There are several means by which cells communicate
to each other, either by direct cell interactions through membrane receptors and ligands, or by releasing soluble
molecules, such as growth factors, cytokines and chemokines. More recently, additional means of cell
communication have been identified, such as microRNAs and extracellular vesicles. These two peculiar ways of cell-
to-cell interaction were the focus of the 31st Annual Conference of the Italian Association of Cell Cultures (AICC).
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Presentation of the conference
The 31st Annual Conference of the Italian Association
of Cell Cultures (AICC), entitled “Cell Communication
and Signaling: how to turn bad language into positive
one” was held in Bologna, at the Rizzoli Orthopaedic
Institute on November 27th and 28th, 2018. Katia Sco-
tlandi, President of AICC, from the Rizzoli Orthopaedic
Institute, and Alessandra Care’ from the Istituto Super-
iore di Sanità in Rome, were the scientific coordinators
of the meeting.
This year the annual conference was focused on the
different means of cellular communication in cancer,
such as microRNAs (miRNA) and extracellular vesicles,
and on the possibility of taking advantage of these sig-
nals for diagnostic and therapeutic purposes. Indeed,
while the relevance of these means of communications
in fostering tumor growth and dissemination by affecting
distant cellular compartments and rendering cancer a
systemic disease is established by a plethora of studies,
growing evidence is showing that these signals can be
exploited for therapeutic approaches. The conference
also covered the recently developed techniques of 3D
cultures and organoids as systems capable of reprodu-
cing, at least in part, the complexity of an organ or of a
tumor that can be employed as new tool for biomedical
research and application. The meeting was organized in
2 days with four thematic sessions, an opening and a
closing lecture, with the contributions of national and
international speakers. An additional session was dedi-
cated to the exhibitors’ presentation of new technologies
and instruments for exosome isolation, gene expression
profiling from ultra-low sample input, label-free live cell
imaging and real-time live cell metabolic analysis.
Opening lecture
The AICC conference was opened by the lecture of
George Calin, from The University of Texas, MD Ander-
son Cancer Center, in Houston (TX, USA). His lecture,
entitled “About Noam Chomsky, genomic immunity,
non-coding RNAs and diseases”, provided an overview
of his outstanding studies on non-coding RNAs, from
the findings of miRNAs involved in cancer to the evi-
dence of the presence of xeno-miRNAs in humans and
the discovery of transcribed piknons. Along his talk,
Calin gave a “semiotic” view of the genome, which, as a
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sentence, is based on patterns that can be sequences of
nucleic acids or amino acids, instead of alphabet letters.
The non-coding RNA “dictionary” of the human genome
represents a relevant part of it, as most of the
non-coding RNAs have regulatory functions [1]. In the
early 2000’s Calin, when working as post-doc in Carlo
Croce’s lab, significantly contributed to define the rele-
vance of miRNAs, identifying the frequent deletion or
down-regulation of miR-15 and -16 in chronic lympho-
cytic leukemia (CLL) patients and providing the first evi-
dence for the involvement of miRNAs in human tumors
[2, 3]. As a clear example of the contribution of miRNAs
in human cancers, Calin showed his study on miR-155,
in which his group has identified the link between this
miRNA with the tumor suppressor p53 and the role in
therapy resistance [4]. MiR-155 is considered an onco-
genic miRNA and is indeed up-regulated in many hu-
man cancers, including solid tumors and hematological
malignancies. Its expression is increased in more aggres-
sive tumors and correlates with therapy resistance. How-
ever, until Calin’s study, the molecular mechanisms
responsible for miR-155-induced therapy resistance were
not clear. By using in vitro tumor cell lines they firstly
confirmed the association between miR-155 expression
and the resistance to chemotherapeutic agents com-
monly used to treat patients and then they identified a
miR-155/p53-negative feedback loop, involved in
chemo-resistance, by which p53 inhibits the expression
of miR-155 through the direct binding in the down-
stream region of miR-155 that, in turn, binds to the 3′
untranslated regions (UTR) of TP53 gene. Additionally,
Calin showed that the targeting of miR-155 could serve
as adjuvant to standard of care chemotherapy in a lung
cancer in vivo model [4]. Such preclinical results paved
the way for clinical trials testing the safety, tolerability
and pharmacokinetics of LNA-based anti-miR-155
MRG-106 in patients with mycosis fungoides, CLL,
diffuse large B-cell lymphoma or adult T-cell leukemia/
lymphoma.
Over the past decade, the crosstalk between tumor
microenvironment and cancer has been largely explored,
as previously discussed in the 30th annual conference of
AICC at Fondazione IRCCS Istituto Nazionale Tumori
(Milan, Italy) in 2017 [5]. In this context, Calin
highlighted the functional association between cancer
development and circulating small and long non-coding
RNAs. He actively contributed to the finding of “foreign”
miRNAs encoded by non-human genomes (so-called
xeno-miRNAs), such as viral miRNAs, in human body
fluids that can be used as biomarkers [6]. Indeed, he
showed data on the differential expression of viral miR-
NAs in the plasma of patients early post-surgery and in
sepsis in comparison with healthy volunteers and their
functional involvement in sepsis acting as agonist of
TLR8 in a positive feedback that may lead to cytokine
dysregulation [7]. The measurement of viral miRNAs by
qPCR has the potential to become the gold-standard
method to detect certain occult viral infections in clin-
ical practice, as demonstrated for Kaposi sarcoma herpes
virus (KSHV) using independent multi-institutional
cohorts of plasma samples [7, 8]. Calin then reported
recent finding on piknons, non-random pattern of
repeated elements frequently found in the 3′-UTR of
genes of the human genome [9]. Performing multivariate
analyses of data from colorectal cancer patients, Calin
and colleagues found that N-BLR, a primate-specific
long non-coding RNA, facilitates migration primarily via
crosstalk with E-cadherin and ZEB1. They showed that
this crosstalk is mediated by a pyknon, a short ~ 20
nucleotide-long DNA motif contained in the N-BLR
transcript and is targeted by members of the miR-200
family [10]. By using a microarray approach they found
multiple such loci that are differentially transcribed
between healthy and cancer tissues, identifying several
new loci whose expression correlates with the colorectal
cancer patients’ overall survival [10]. In the conclusion
of his lecture on the evolutionary medicine in tumor
biology, Calin introduced the concept of genomic
immunity in which pervasive non-coding RNAs, such as
pyknons, provide genomic protection. When this
finely-tuned system is malfunctioning, because of an ex-
cess of viral miRNAs or a reduction in the pyknons
levels, a pathological condition, such as viral infection,
sepsis, cancer or auto-immune disease, can occur.
Session 1. CIRCULATING SIGNALS AND CANCER
The advent of genomic-based precision medicine led to
the implementation of biomarker testing in cancer. Bio-
markers are the key to personalized treatment in cancer
patients. In recent years, much of the research on blood
biomarkers in cancer has shifted from protein-based to
nucleic acid-based molecules. DNA and RNA, like pro-
teins, are released from tumors into the bloodstream.
Compared to tissue-based biomarker analysis, that still
represents the gold standard, the use of cell-free nucleic
acids allows minimal invasive access and ease of serial
monitoring, in particular when tumor tissue is not avail-
able, or it is insufficient for molecular testing. To date,
the use of liquid biopsy refers to those tests performed
on body fluids aiming to determine prognosis and pre-
dict responses to therapy. Although in most situations
biomarkers tend to increase with disease progression
and decrease with regression, paradoxical increases,
known as spikes or surges, can occur after the com-
mencement of chemotherapy, especially in patients with
extensive metastatic burden. These transient increases
are usually not related to tumor progression but appear
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to be the result from therapy-induced apoptosis or
necrosis of tumor cells.
Circulating miRNAs turned out to be good biomarkers
for cancers because they regulate gene expression and
are involved in cancer initiation and development
(Fig. 1a). In addition, miRNAs are easy to detect, and
sampling blood or serum is non-invasive and simple to
implement. Nevertheless, the definition of reproducible
and reliable biomarkers to be applied in clinical practice
is still far. miRNA expression levels in biofluids are af-
fected by a range of pre-analytical and analytical chal-
lenges in experimental design, from sample collection to
data analysis, all contributing to the extremely poor
agreement between the circulating miRNA signatures
reported by different research groups. In this context
Gabriella Sozzi from Fondazione IRCCS Istituto Nazio-
nale dei Tumori in Milan (Italy), reported data from her
Institution by the use of a liquid biopsy approach that
brought to the development of a minimally invasive
molecular test, based on miRNA evaluation in plasma,
useful for risk assessment and early detection of Lung
cancer (LC). They identified a plasma miRNA signature
(miRNA Signature Classifier, MSC) composed of 24
miRNAs which showed high performance in terms of
sensitivity and specificity in subjects enrolled in two
independent screening trials for LC with a combined
low-dose computed tomography (LDCT) [11]. These
results prompted the researchers to launch in 2013 a
unique prospective trial, called bioMILD (http://www.
biomild.org), to test the efficiency of a LDCT-MSC ap-
proach as first-line screening tests in a large cohort of
4000 smokers, 50 years or older. In the study design, the
combination of the results from the two tests determines
the subsequent diagnostic course. Interestingly, the MSC
was developed using plasma samples collected longitu-
dinally along the trial and the classifier was able to
Fig. 1 The utility of miRNAs in diagnosis and therapy. miRNAs can be harvested from biological fluids and used as liquid biopsies, in which free
circulating miRNAs or exosomal miRNAs can be captured and analyzed ex vivo (a). They have proved useful biomarkers for diagnosis, prognosis,
personalized therapies or disease monitoring. miRNAs can also be employed as therapeutics or therapeutic targets: miRNA mimics can be used
for replacement therapies by the use of delivery systems while miRNA inhibitors, such as locked nucleic acid-antisense oligonucleotides, for
inhibition approaches (b)
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identify a risk profile to develop lung cancer up to 2
years before a significant tumor burden was visible [12].
This observation led the researchers to hypothesize
that such circulating miRNAs could be released not
merely by cancer cells but rather by the damaged lung
microenvironment and the host immune cells that may
sustain tumor development. Thus, such signals could
represent very early changes reflecting the biological re-
action of the host to cancer development. Sozzi’s group
recently focused the attention in understanding the
source and contribution of different cell types to the
pool of circulating miRNAs using both in vitro models
and clinical samples. They observed a cell-type specific
expression and topography of several miRNAs in lung
normal and cancer tissues and changes of miRNA levels
during phenotype modulation of immune and stromal
cells, consistent with deregulation of the same miRNAs
in plasma of LC subjects. Since miR-320 was the miRNA
most overexpressed in activated neutrophils and in
agreement with its high level in the plasma of
MSC-positive subjects, the authors focused on this
miRNA for further studies. They found that miR-320
levels were significantly associated to polymorpho-
nuclear (PMN) cells count in the blood of lung cancer
screening patients and its expression levels were higher
in neutrophils isolated from MSC-positive subjects,
either in cells and in the culture medium, as well as in
exosomes. Moreover, the authors showed that miR-320
secreted by PMNs is shuttled into macrophages promot-
ing M2 pro-tumorigenic phenotype through STAT4
down-modulation, thus proving that circulating miRNAs
may act in paracrine signaling and have a functional role
in lung carcinogenesis and immunosuppression [13]. At
the end of her talk, Gabriella Sozzi showed the possible
utility of MSC in LC immunotherapy settings. Using a
cohort of 140 consecutive advanced NSCLC patients
treated with immune checkpoint inhibitors they found
that the combination of plasma MSC risk level and
PD-L1 expression in the tumor was associated with
patients survival [14]. The conclusion of Gabriella Sozzi
supports the hypothesis that plasma MSC, reflecting an
impaired tumor immune contexture, could complement
PD-L1 tumor expression for the identification of a sub-
group of patients who do not benefit from immunotherapy.
MiRNA are broadly deregulated in many types of
tumor where they affect all the hallmarks of cancer, sus-
taining proliferative signaling, evading growth suppres-
sors, resisting to cell death, activating invasion and
metastasis, and inducing angiogenesis. An increasing
number of researches identified miRNAs not only as
potential biomarkers for diagnosis or prognosis of hu-
man cancer, but also as therapeutic targets or tools [15]
(Fig. 1b). In this context, Massimo Negrini from
University of Ferrara (Italy) presented a hepatocellular
carcinoma (HCC) model for miRNA therapeutic investiga-
tion. Negrini’s group developed a transgenic (TG) mouse
model carrying a liver-deregulated miR-221 (TG221), char-
acterized by the occurrence of spontaneous nodular lesions
in the liver of approximately 50% of male mice and by a
strong acceleration of tumor development in mice treated
with diethylnitrosamine (DENA). This animal model has
been used to investigate the role of two miRNAs that are
deeply deregulated in human hepatocarcinoma. First, they
investigated the therapeutic activity of an anti-miRNA
oligonucleotide (AMO) against miR-221 in TG221 mice
and observed a significant reduction in the number and
size of lesions in anti-miR-221-treated mice compared to
mice treated with DENA only, together with a persistent
decrease of miR-221 levels in liver of the AMO-treated
mice [16]. The TG221 HCC mouse model was also
employed for a miRNA replacement approach, to restore
miR-199 expression that is down-regulated in human
HCC, using a miR-199a-3p unmodified single-stranded
RNA oligonucleotide. The in vivo delivery of the
miR-199a-3p mimic was facilitated by the use of lipid
nanoparticles as vehicle. The antitumor activity in TG221
mice was evaluated in comparison with a miRNA scram-
bled control and sorafenib tosylate treatments. Administra-
tion of miR-199a-3p mimics in the TG221 transgenic
mouse bearing liver cancer led to a significant reduction in
both number and size of tumor nodules compared to
control animals. Further analysis confirmed in the liver of
treated mice a down-regulation of the miR-199a-3p direct
targets, such as mammalian target of rapamycin (mTOR)
and p21 activated kinase 4 (PAK4), ultimately leading to
the repression of FOXM1 [17]. Remarkably, the anti-tumor
activity of miR-199a-3p mimic was comparable to that
obtained with sorafenib. These results suggest that
miR-199a-3p may be considered a promising HCC thera-
peutic option. Interestingly, the TG221 mouse treated with
carbon tetrachloride was found to recapitulate the
fibrosis-cirrhosis-HCC natural history seen in human. In
this experimental setting, the model was used to evaluate if
miRNA-based therapies can prevent liver cancer. The data
presented by Massimo Negrini indicate that anti-miR-221
or miR-199 mimics prophylaxis is able to reduce nodule
size and malignant potential (Shankaraja et al., unpublished
data), suggesting that tumor prevention could represent
the setting in which these molecules could work best.
However, they also indicate that re-expression of multiple
miRNAs is needed to fully prevent the appearance of
tumors in this mouse model. The natural history of HCC
development suggests the possibility of applying miRNAs
prophylaxis protocols.
Session 2. Tumor-microenvironment interactions
Cell communication has a fundamental role in allowing
cancer cell to coopt and modulate stromal and immune
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cells. The active crosstalk between the tumor and the
surrounding cells fosters angiogenesis, immune-escape,
epithelial-to-mesenchymal transition, formation of a
pre-metastatic niche, metastases and multi-drug resist-
ance. Cell communication can occur either through dir-
ect cell interactions or by the release of soluble factors,
such as cytokines, growth factors and chemokines. A
noteworthy way of communication between tumor cells
and the tumor microenvironment (TME) is represented
by extracellular vesicles (EVs).
EVs are circular fragments of membranes that carry
various bioactive molecules including membrane recep-
tors, proteins, mRNAs, microRNAs, and organelles, thus
being able to stimulate target cells by receptor-to-ligand
interaction or by transferring their cargo. The most
studied EVs are the exosomes, which are derived from a
process of fusion between intracellular organelles (i.e.
endosomes and lysosomes) and plasma membrane as
well. Exosomes released from cancerous cells, with their
cargo of growth factors, cytokines, angiogenic molecules,
miRNAs, and immunosuppressive factors, actively con-
tribute to tumor progression and dissemination (Fig. 2).
The first presentation in the session was given by Ste-
fano Fais, from Istituto Superiore di Sanità, in Rome
(Italy), who focused on the effects of tumor acidity on
exosome release from tumor cells. He started from
previous observations by his group: tumors are acidic,
because neoplastic cells are able to generate energy by
non-oxidative breakdown of glucose, and proton pump
inhibitors are able to rescue tumor acidity to normal pH
levels, both in vitro and in vivo, thus opening a route for
a therapeutic use of these inhibitors in association with
chemotherapy in various refractory tumors [18, 19]. Not-
ably, Stefano Fais has recently demonstrated that tumor
low pH has an impact on exosome release and traffick-
ing. His group investigated the role of tumor pH in
regulating exosome release from tumor cells in the con-
text of prostate cancer (PCa) by performing both Nano-
particle Tracking Analysis (NTA) and nanoscale
flow-cytometry [20]. In vitro, when prostatic cancer cells
were cultured in acidic medium, an increased release of
nanovesicles, positive for both PSA and the exosome
marker CD81, was observed. Interestingly, in plasma from
prostate cancer patients, the concentration of PSA+-exo-
some resulted higher than in healthy donors and subjects
with benign prostatic hyperplasia, indicating that tumor
microenvironmental acidity has an impact on exosome re-
lease in vivo [20]. Moreover, the increased release of exo-
somes from tumor cells was not a specific feature of PCa
but is a common feature of all cancers [21]. Overall, his
data indicate that treatment with proton pump inhibitors
may dramatically impact on tumor-TME communication,
by inhibiting exosome release, and hence may represent a
new therapeutic strategy in cancer.
Fig. 2 The Yin and Yang of exosomes. Exosomes are released by a variety of cell types, including cancerous cells. In this context, exosomes
contribute to tumor progression and dissemination. Indeed, they carry malignant information in form of nucleic acids, either mRNAs or miRNAs,
or proteins, such as growth factors, cytokines, chemokines, or angiogenic and immuno-regulatory molecules. Through their cargo cancer-derived
exosomes can foster different aspects of tumor growth, as neo-vascularization, immune suppression, invasion, dissemination and pre-metastatic
niche formation. On the other hand, exosomes, in light of their structure, can be considered as a new generation of a natural nanoscale delivery
systems and exploited for therapeutic approaches. Specific cell types can be genetically modified and used as cell factories for the production of
armed exosomes, for example carrying onco-suppressor miRNAs, or shRNA, or targeted exosomes, carrying receptors or antibodies for binding to
specific cell types. Furthermore, the exosome liposome-like structure allows them to be loaded with various drugs
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Anna Maria Teti, from University of L’Aquila (Italy),
presented data on a fascinating aspect of tumor-TME
cross-talk, the interaction between the endosteal niche
and tumor dormancy. In the endosteal niche, spindle-
shaped N-cadherin+CD45- osteoblastic (SNO) cells,
which are located mainly on the surface of cancellous/
trabecular bones, are associated with N-cadherin+ stem
cells (HSC) and support their growth through specific
interaction between N-cadherin and β-catenin [22]. The
TME has a key role in determining the ultimate fate of
tumor cells, including dormancy of metastatic cancer
cells. Late recurrence is particularly relevant in breast
cancer and one of the preferred site of breast cancer me-
tastasis is indeed the bone [23]. The study done by Teti’s
group aimed at clarifying the mechanisms of breast can-
cer dormancy in the bone and the role of bone marrow
microenvironment in this phenomenon. She demon-
strated that SNO cells are cell cycle-arrested, poorly dif-
ferentiated osteoblasts, which express the Notch2 ligand
Jagged1. In in vivo experiments, they observed the en-
graftment of single cell cycle arrested breast cancer cells
close to endosteal SNO cells, thus suggesting a role of
the endosteal TME in supporting breast cancer cell
dormancy. This hypothesis was confirmed by in vitro
experiments showing that breast cancer cells plated on
SNO cells reduced their own proliferative rate and
expressed high level of Notch2. The involvement of
Notch signaling in this context was formally demon-
strated by Notch inhibition. In fact, Notch2high breast
cancer cells, grown with SNO cells, rescued their prolif-
erative rate in presence of Notch inhibitors and acquired
HSC mimicry and stem cell phenotype. Additionally,
these cells were resistant to chemotherapy treatment. To
complete this picture, Anna Teti showed that Notch2high
breast cancer cells generate less bone and liver metasta-
sis in vivo, and that Notch inhibition was able to reacti-
vate dormant breast cancer cells and promote metastatic
dissemination to the liver. In agreement with those pre-
clinical results, at the end of her presentation she showed
that in breast cancer patients, high expression of Notch2
is correlated with better prognosis, thus potentially repre-
senting a new prognostic marker for recurrence.
The last invited speaker of this session, Giovanni
Camussi from University of Turin (Italy), highlighted
another interesting aspect of tumor-TME interaction re-
garding the ability of tumor-derived extracellular vesicles
(EVs) to trigger angiogenesis and promote the formation
of a pre-metastatic niche. He showed that renal carcin-
oma stem cells, positive for the mesenchymal stem cell
marker CD105, were able to stimulate the growth and
induce an angiogenic phenotype in normal lung endo-
thelial cells [24]. These effects were due to an epigenetic
modification of endothelial cells mediated by cancer
stem cells (CSC)-derived EVs. EVs are able, indeed, to
transfer miRNAs and RNA-binding proteins from CSC
to other cells in the TME. In the context of renal carcin-
oma, Giovanni Camussi demonstrated an up-regulation
of 24 miRNA and a down-regulation of 33 miRNA in
CD105+ EVs in comparison to CD105− EVs. Many of
these miRNAs are known to be associated with tumor
invasion and metastasis and have been shown to be
deregulated in renal carcinoma and in other tumors.
Indeed, he reported that CD105+ EVs, but not CD105−
EVs, carry mRNAs for genes involved in angiogenesis
such as VEGF, FGF2, angiopoietin1, ephrin A3, MMP2
and MMP9. These vesicles also significantly enhanced
the expression of VEGFR1, VEGF and MMP2 in lung
endothelial cells and of MMP9 in the whole lung in vivo,
thus favoring the formation of a lung pre-metastatic
niche [24]. CD105+ EVs are able to promote phenotypic
changes not only in endothelial cells but also in mesen-
chymal stromal cells (MSCs). Indeed, in vivo experiments
in which renal tumor cells were co-injected with
EV-stimulated MSCs demonstrated a role for CD105+ EVs
in supporting tumor development and vascularization
[25]. Another key aspect of tumor progression is the
ability of cancer cells to down-modulate the immune re-
sponse. Giovanni Camussi ended his talk showing that
CD105+ EVs play a role also in this aspect, demonstrating
that CD105+ EVs impair maturation of DCs and T cell
immune response by a mechanism involving HLA-G [26].
Session 3. Clinical potential of exosomes
The delivery of drugs or other agents specifically to
pathological tissues is one of the challenges of medicine
for the treatment of neoplastic and inflammatory diseases.
In this context, the use of nanocarriers can be useful in
light of the ability of nanoscale materials to trespass the
fenestrated vessels of inflammatory and cancer tissues and
to accumulate in these tissues because of the lack of
lymphatic drainage (the so-called enhanced permeation
and retention effect) [27]. In addition, the development of
functional nanomaterials is of great importance and
significance for the active targeting and re-targeting of the
affected tissues. Nevertheless, exogenous nanomaterials
have a tendency of inducing undesired immune responses
and nano-protein interactions, which may result in tox-
icity and therapy failure. Exosomes can be considered as a
new generation of a natural nanoscale delivery system.
Indeed, exosomes secreted by different types of cells carry
different signaling molecules (such as RNAs and proteins)
and thus have a great potential for targeted drug delivery
and therapy [28] (Fig. 2). Furthermore, the exosome
liposome-like structure allows them to be loaded with
various drugs. Hence, the potential of exosomes in drug
delivery, tumor-targeted therapy, and immunotherapy has
been widely investigated in recent years [29].
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In this session, the clinical perspective on exosome-
based therapeutic strategies has been discussed, starting
from the description of artificial nanocarriers, niosomes,
similar to exosomes for composition and delivery prop-
erties, discussed in this session by Maria Carafa, from La
Sapienza University of Rome (Italy). Niosomes are
non-ionic surfactant-based vesicles [30] that can be
considered a novel drug delivery system. The twofold
structure of surfactant molecules encourages them to
orient in a bilayer architecture. In this two-layered struc-
ture, hydrophilic and hydrophobic ends of surfactant
tend to arrange into external and internal sites, respect-
ively. The most used surfactants are SPAN, TWEEN and
BRIJ [31]. This lamellar morphology allows them to
entrap different types of drugs in a unique carrier simul-
taneously. Several factors can affect the structure of
niosomes, such as the nature and type of surfactants, the
amount of cholesterol, the critical packing parameter
and the drug used [32]. In the end of her presentation,
Maria Carafa underscored the fact that nanocarriers are
dinamically interacting with other biological entities,
such as proteins, cell membranes and intracellular
compartments, and therefore understanding the fate of
nanocarriers is a necessary step for optimizing their de-
sign in order to deliver cargo molecules more effectively
and with better targeting actions [33, 34].
Niosomes can be designed in order to be administered
via different routes, such as oral, topical, and employed
for dermal and transdermal delivery, for ocular, oral,
lung and parenteral delivery, and used for gene delivery,
diagnostics/theranostics and for natural product encap-
sulation. Although niosomes are similar to liposomes in
structure, niosomes are more stable and also more
cost-effective than liposomes and remain in the blood-
stream for a reasonable time, which is useful for targeted
drug delivery.
The second presentation, held by Simona Fontana
from the University of Palermo (Italy), focused on the
role of tumor-derived exosomes (TDEs) in cancer signal-
ling and progression. Indeed, an important emerging
function of exosomes secreted by tumor cells is the
ability to influence the biological behavior of other cells,
either neoplastic or normal cells not only in the
surrounding tumor microenvironment but also, being
released in the blood stream, in distant districts. In this
context, several pieces of evidence indicate an active role
for TDEs in the establishment of the pre-metastatic
niche. Simona Fontana presented data on the crosstalk
between cellular elements of the bone marrow micro-
environment and tumor cells in the context of chronic
myeloid leukemia (CML), which affects disease progres-
sion. Such crosstalk occurs through soluble factors (cy-
tokines and growth factors) and extracellular matrix
components. Angiogenesis is a key step for the
progression of CML, and she showed results on the role
of exosomes in this process. She showed that the
addition of exosomes to human vascular endothelial
cells (HUVEC) in vitro induces an increase of ICAM-1
and VCAM-1 cell adhesion molecules and of IL-8
expression [35] and that exosomes released from CML
cells stimulate bone marrow stromal cells to produce IL
8 that, in turn, modulates the leukemia cell malignant
phenotype [36]. On the same line, but in different tumor
histotypes, she showed that TDEs from multiple mye-
loma and lung cancer cells drive osteoclast differenti-
ation in RAW264.7 macrophagic cells. In the context of
lung cancer, she showed that such effect is mediated by
amphiregulin contained in NSCLC exosomes that
activates the EGFR pathway [37]. Additionally, using two
isogenic human colon cancer cell lines, established from
the same colon cancer patient, she showed that TDEs
derived from metastatic cells are able to induce the
phenotypic switch of non-metastatic elements by eliciting
the mesenchymal to amoeboid transition [38]. Finally,
circulating TDEs can represent useful biomarkers to de-
fine the molecular signature of a tumour (liquid biopsy)
and tools for therapeutic application as delivery systems
for drugs, miRNAs, or immunotherapeutic agents.
Session 4. 3D-organoids models as new tools for
biomedical research and application
In recent years, a high technological development has
been achieved through the use of three-dimension (3D)
techniques, molded scaffolds and organoids, in order to
obtain experimental models better resembling the real
biological settings [39]. The reason that prompted re-
searchers to improve cell culture from two-dimension
(2D) to 3D lies in the fact that 2D condition does not re-
produce tissue architecture and cellular heterogeneity.
Organoids are structures composed of different types of
self-organized cells to better mimic embryonic and tis-
sue development in vitro. The 3D model has proven to
be superior compared to conventional cellular models,
as it presents architecture and geometric characteristics
of the tissues observed in vivo, thus allowing a better
evaluation of the response to drugs are used in transla-
tional, personalized and regenerative medicine [40].
Tissue engineering is an innovative new therapeutic
strategy based on the combination of cells, suitable bio-
materials and growth factors used to improve or replace
biological structures. Cells can be isolated from different
tissues such as bone marrow, fat and synovia, peripheral
blood, placenta, umbilical cord and embryo. Mesenchy-
mal stem cells can be isolated, expanded in vitro and
they need to survive without malignant transformation.
In recent years, there have been huge technological ad-
vances in scaffold development through the production of
natural and synthetic polymers. Natural or recombinant
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polymers, plus anabolic factors and platelet-rich plasma,
are used to favor and regulate different cellular processes
such as proliferation, differentiation and synthesis of spe-
cific tissue matrix molecules [41]. In this contest, Brunella
Grigolo from IRCCS Istituto Ortopedico Rizzoli, Bologna
(Italy), presented data on a meniscus prototype obtained
with the use of the 3D bioprinting technique [42]. The
meniscus serves many important biomechanical functions,
it contributes to load transmission, shock absorption,
nutrition, joint lubrication, and proprioception. Damage
to the meniscus can be of different types and origins, like
acute tears due to trauma or sport injuries, or chronic
tears, most often occurring in elderly people, and degen-
erative meniscal tears that occur after minimal trauma or
stress on the knee. Three dimensional (3D) bioprinting is
a technique that uses 3D printing technologies to combine
cells, growth factors, and biomaterials within a single
“bio-ink”, in order to fabricate structures capable of repli-
cating natural tissue characteristics. Patient data are
obtained by digital imaging and processed by specific soft-
ware. The presented study reported that 3D bioprinter
was able to produce a meniscus made by Collagen Type I
(size 5mm) that could be seeded with human mesenchy-
mal stem cells and that could represent the starting point
for future developments toward the optimization of
implants to replace damaged structures.
Recent advances in human-derived 3D cultures for
studies on bone metastasis were nicely presented by
Milena Fini from IRCCS Istituto Ortopedico Rizzoli,
Bologna, (Italy). She explained the complexity of the
interaction between tumor cells that metastasize in the
bone inducing destructive osteolytic and/or bone form-
ing osteoblastic lesions and the alteration of bone micro-
environment producing factors that stimulate tumor
growth [43]. When bone metastases were initially stud-
ied, one of the limitations was the complex nature of the
bone environment. Up-to-now, there are no commer-
cially available models able to mimic the biological
processes occurring in patients. To improve the under-
standing of these phenomena and the interpretation of
the results, Fini’s group obtained an in vitro three-di-
mensional (3D) bone metastasis model by culturing hu-
man breast or prostate cancer cells with human bone
tissue isolated from female and male patients, respect-
ively. Gene expression profile, protein levels, histological,
immunohistochemical and four dimensional (4D)
micro-CT analyses showed a noticeable specificity of
breast and prostate cancer cells for bone colonization
and ingrowth, thus highlighting the species specific and
sex-specific osteotropism [44]. Additionally, using this in
vitro model, Fini’s group evaluated also the influence of
bone remodeling rate, recognizing major differences in
tumor growth and colonization between healthy and
osteoporotic status. They showed that the altered bone
microenvironment due to osteoporosis stimulates tumor
cell colonization indicating that the mechanisms direct-
ing breast cancer progression could be influenced also
by the endocrine status of the patient [45]. These 3D
models will be important for the development of new
complex cell systems to study the physiological events
that occur when cancer cells meet and interact with the
bone environment.
Currently there are very few studies on tissue culture
models to mimic metastasis of colorectal cancer (CRC)
to liver. Most studies on liver colonization are per-
formed in 2D conventional culture models or xenograft
models. The 2D culture models fail to recapitulate the
pathophysiological gradients of oxygen, nutrient/waste
and drug and the cell-extracellular matrix (ECM) inter-
action occurring in a physiological in vivo setting. The
animal model has the advantage of providing a 3D envir-
onment with complex cell-cell and cell-ECM interac-
tions. In this contest, Marco Agostini from University of
Padua, Padua (Italy), presented a new method of tissue
decellularization. This method is widely used in tissue
engineering with the aim of creating an a-cellular
scaffold that, once repopulated with autologous cells, is
re-implanted in the patient to restore the functions of
the damaged tissue [46]. Progresses in decellularization
techniques provide novel approaches for isolating
patient-derived ECM. Three-dimensional cancer models
could be used to investigate CRC pathogenesis, progres-
sion and treatment response. Only recently, the decellu-
larization process has been applied to the study of
tumor progression. The goal of the study presented by
Marco Agostini was to develop an in vitro patient-de-
rived 3D bioactive model of colon cancer liver metastasis
(CRLM). As initial step, the attention was focused on re-
producing the structural and biochemical microenviron-
ment of CRLM by assessing nuclei depletion and
preservation of ECM biochemical and biophysical
characteristics. Moreover, immunohistochemical analysis
showed that the expression and distribution of key ECM
components, such as collagen and glycosaminoglycan,
were maintained in the decellularized healthy liver (HL)
and colorectal cancer liver metastasis (CRLM) compared
to native fresh tissue. A real-time non-invasive technique
was used to monitor and analyze cell behavior in the
metastatic scaffold. Finally, to evaluate whether the
patient-derived decellularized scaffolds retained the bio-
logical functionality of the native tissue, Luc-ZsGreen+
HT-29 cells were cultured in CRC and CRLM scaffolds,
using their respective healthy samples as controls. The
results suggested that the ECM of the different scaffolds
influenced the behavior of CRC-derived cells. To evalu-
ate if CRLM scaffold induced a pro-migration stimulus
to CRC cells, cells were labeled with an antibody to
E-cadherin, which is critical for the formation and
Chiodoni et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:128 Page 8 of 11
maintenance of adhesion of epithelial cell-cell contact
and loss of its expression could indicate transition
between benign to metastatic tumors. CRC cells showed
a specific organotypic reduction of E-cadherin expres-
sion only in CRLM recellularized scaffolds, compared to
HL and CRC. These data provide important indications
on the possible use of detergent-enzymatic methods to
effectively decellularize healthy and metastatic tissue,
preserving the tissue structure and architecture.
Gina Lisignoli from IRCCS Istituto Ortopedico Rizzoli,
Bologna (Italy) addressed the issue of development of an
in vitro co-culture model for mesenchymal stem cells
and synoviocytes focusing on the need to develop a 3D
in vitro osteoarthritic (OA) synovial model for studying
the role of synovial cells and of their ECM [47, 48].
Healthy synovial membrane is the soft tissue lining the
spaces of diarthrodial joints, tendon sheaths and bursae.
Synovitis is characterized by synovial lining hyperplasia,
sub-intima fibrosis, stromal vascularization and abun-
dant influx of leukocyte. The synovial membrane is stud-
ied in vitro by synovial fibroblasts monolayer or cell line
(i.e. K4IM) but these models do not take in consider-
ation the role of synovial macrophages or ECM. Synovial
explants have the benefit of native synovial membrane
structure, but they show high variability and limited
amount of samples. Up to now, there is a lack of in vitro
systems that represent the pathological synovial tissue.
Thus, the development of engineered synovial tissues
may help overcoming these limitations. Intra-articular
injections of adipose-derived mesenchymal stem cells
(ASC) in osteoarthritis animal models reduced inflam-
mation and macrophage markers by specifically adhering
to synovial macrophages. Lisignoli underscored the im-
portance of using specific cells able to recreate a milieu
that more closely resembles the characteristics of OA
synovial tissue. Moreover, the availability of in vitro cell
models (synoviocytes) that better reflect the different
degrees of OA synovial inflammation could give the
opportunity of testing cells or anti-inflammatory drugs
in a well-defined and more predictive milieu. At the end,
the development of a 3D engineered in vitro synovial
membrane model could better reproduced the physio-
logical characteristics of the native tissue and provide a
platform able to mimics structural changes occurring at
different degree stages.
Closing lecture and remarks
In the closing lecture of the meeting, Susanne Gabriels-
son from the Karolinska Institute (Stockholm, Sweden)
addressed the role of exosomes, extracellular nanovesi-
cles which origin from the endosomal compartment and
that can carry immunostimulatory molecules, as poten-
tial immunotherapeutics for cancer treatment. After a
general introduction on exosomes and on the different
technologies currently available for their analysis, Susanne
Gabrielsson focused her presentation on the feasibility of
using Exo in clinical cancer therapy, and mentioned the
few clinical trials performed with dendritic cell (DC)-der-
ived exosomes. She described the model system used in
her laboratory to measure the immune response elicited
by exosomes obtained from ovalbumin (OVA)-loaded DC,
stressing the requirement for the presence of the whole
antigen in vivo for an efficient immune response, not
obtained when the specific peptide is used [49, 50].
Susanne Gabrielsson presented data on how to im-
prove the immunogenicity of DC-derived exosomes by
loading DC with the antigen and the iNKT-cell ligand
αGalCer (αGC) [51, 52]. In particular, she showed that
Exo-OVA/αGC administered intravenously in C57BL/6
mice were able to decrease tumor growth of B16-OVA
tumors, and increased antigen-specific CD8 T-cell
tumor infiltration and survival, relative to control mice.
Interestingly, the number of injections resulted to be
critical for the induction of an efficient immune re-
sponse, as a double shot was able to elicit a production
of antibodies with higher avidity compared to a single
injection. This aspect should be considered in view of
clinical application of the strategy. She went on pre-
senting details on the mechanisms of the response,
showing the independency from the MHC of the exo-
some [53], the requirement of both T and B cells for
the immune response [54] and the possibility of using
allogeneic exosomes that are equally effective as syn-
geneic exosomes in the B16 melanoma model. In con-
clusion, her results obtained in pre-clinical mouse
models suggest the possibility of using exosomes for
therapeutic purpose in humans.
In conclusion, the 31st Annual Conference of the
Italian Association for Cell Cultures, hosted at the
Rizzoli Orthopedic Institute, one of the most import-
ant institution in this area of medicine in Italy and in
Europe, has seen more than 100 participants. Most of
them were young researchers who had the chance to
learn on the role of cell communication and signaling
in pathological conditions and as means for potential
therapeutic vehicles, as well as to share their ideas
and knowledge in the field. This has been made
possible by brilliant presentations from outstanding
invited speakers, selected talks and during the inter-
active poster sessions.
At the end of the conference, as a well-established
tradition for AICC, 5 young researchers received prized
for either best posters or oral presentation from Fonda-
zione Berlucchi, the Journal of Experimental and Clinical
Cancer Research and AICC. We would like to congratu-
late with the young recipients of the scientific awards
and thank all the attendees of the 31st AICC Annual
Conference.
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